Automatic Data Processing Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Automatic Data Processing Inc trades at $272 (market cap $108.72B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Automatic Data Processing Inc pays a 2.48% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ADP | VRTX | |
|---|---|---|
Market Cap | $108.72B | $132.79B |
Sector | Industrials | Health |
52-Week High | $309.03 | $529.65 |
52-Week Low | $188.79 | $376.62 |
Enterprise Value | $109.76B | $126.92B |
Dividend Yield | 2.48% | — |
Signals from Pluang's Aura AI — not financial advice
ADP trades at $271.32, down 0.8% for the day, with strong technical momentum showing bullish moving averages and key support at $269. The company demonstrates robust fundamentals with consistent earnings beats, 20.11% net margins, and 72.24% ROE. Recent Q4 2026 results showed 7% revenue growth and 17% EPS growth, driving positive analyst sentiment despite elevated valuation multiples.
Outlook remains positive with a $280.50 consensus price target offering 3.4% upside potential. Key opportunities include margin expansion and dividend stability, while risks center on high valuation sensitivity and labor market volatility affecting ADP's payroll processing business. The stock presents a quality growth opportunity with disciplined risk management required.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Trailing returns across standard periods
Latest headlines on both assets
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →